Progress in the treatment of chronic hepatitis C virus genotype 3 infection

VernacularTitle:基因3型慢性丙型肝炎治疗进展
Author: Xiaoting ZHAO ¹ ; Zebing HUANG ; Yan HUANG
Author Information

1. 中南大学湘雅医院感染病科，长沙　410031
Keywords: Hepatitis C virus; Genotype 3; Direct antiviral drugs; Sustained virological response
From: Chinese Journal of Clinical Infectious Diseases 2021;14(6):468-474
CountryChina
Language:Chinese
Abstract: Hepatitis C virus genotype 3 (HCV G3) infection is the second most prevalent hepatitis C genotype globally, with higher rates of disease progression and mortality compared with other genotypes. After the advent of direct-acting antiviral drugs (DAAs), the efficacy of antiviral therapy for hepatitis C patients has been greatly improved, but the therapy for G3 type is less effective than that for other genotypes, so it is considered to be one of the most difficult subtypes to treat. This article reviews the available treatment options for HCV G3 patients and their sustained virological response rates to provide clinical reference.